Agios Pharmaceuticals Inc EV/EBITDA
¿Qué es el EV/EBITDA de Agios Pharmaceuticals Inc?
El EV/EBITDA de Agios Pharmaceuticals Inc es N/A
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en NASDAQ en comparadas con Agios Pharmaceuticals Inc
¿Qué hace Agios Pharmaceuticals Inc?
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Empresas con ev/ebitda similar a Agios Pharmaceuticals Inc
- Perk Labs tiene EV/EBITDA de N/A
- Canterra Minerals tiene EV/EBITDA de N/A
- Xortx Therapeutics Inc tiene EV/EBITDA de N/A
- Comstock Metals Ltd tiene EV/EBITDA de N/A
- Binovi Technologies tiene EV/EBITDA de N/A
- RYU Apparel tiene EV/EBITDA de N/A
- Agios Pharmaceuticals Inc tiene EV/EBITDA de N/A
- Next Hydrogen Solutions tiene EV/EBITDA de N/A
- Roots Sustainable Agricultural Technologies tiene EV/EBITDA de N/A
- Emperor Capital tiene EV/EBITDA de N/A
- Total Gabon tiene EV/EBITDA de N/A
- China Uptown tiene EV/EBITDA de N/A
- Argonaut Resources NL tiene EV/EBITDA de N/A